Nelliebear personal page - To The Moon

Nelliebear

No personal profile

3Follow

1Followers

0Topic

0Badge

2023-03-16

Keep the faith

Sorry, the original content has been removed

2022-12-20

💪

Sorry, the original content has been removed

2022-12-14

👍

Sorry, the original content has been removed

2022-12-14

👍

Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial

2022-10-07

👍

Sorry, the original content has been removed

2022-09-22

Keep going 👍

Sorry, the original content has been removed

2022-09-20

Keep going 👍

Sorry, the original content has been removed

2022-09-19

Keep going 💪

U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder

2022-09-15

Keep going 💪

Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants

2022-09-15

💪 Keep going

Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery

2022-09-07

Keep going 💪

Sorry, the original content has been removed

2022-09-07

Keep going 💪

Sorry, the original content has been removed

2022-09-02

💪 Keep going

Sorry, the original content has been removed

2022-09-02

💪 Keep going

Sorry, the original content has been removed

2022-08-31

💪💪

BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing

2022-08-26

Keep going

Sorry, the original content has been removed

2022-08-26

Keep going

Sorry, the original content has been removed

2022-08-25

Keep it going

Trending: Bed Bath & Beyond Finds a Lender, Sources Say

2022-08-24

Keep it going

Starbox Shares Jumped 22% in Premarket Trading

2022-08-06

Keep going 👍💪

Applied DNA stock surges again, for 4-day gain of more than 870%

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4099579894850160","uuid":"4099579894850160","gmtCreate":1636476828583,"gmtModify":1636476828583,"name":"Nelliebear","pinyin":"nelliebear","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":40,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9943069212,"gmtCreate":1678970053837,"gmtModify":1678970057873,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep the faith&nbsp;","listText":"Keep the faith&nbsp;","text":"Keep the faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943069212","repostId":"2319635989","repostType":2,"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926346415,"gmtCreate":1671475343437,"gmtModify":1676538542689,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926346415","repostId":"2292878348","repostType":2,"isVote":1,"tweetType":1,"viewCount":1964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919543,"gmtCreate":1670952901482,"gmtModify":1676538466261,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919543","repostId":"2291739039","repostType":2,"isVote":1,"tweetType":1,"viewCount":4025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919295,"gmtCreate":1670952878417,"gmtModify":1676538466259,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919295","repostId":"2291146287","repostType":2,"repost":{"id":"2291146287","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1670867520,"share":"https://ttm.financial/m/news/2291146287?lang=en_US&edition=fundamental","pubTime":"2022-12-13 01:52","market":"us","language":"en","title":"Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2291146287","media":"Dow Jones","summary":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-12-13 01:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRCT":"Cricut, Inc.","BK4139":"生物科技","BK4007":"制药","BK4191":"家用电器","BK4539":"次新股","TERN":"Terns Pharmaceuticals, Inc.","HARP":"Harpoon Therapeutics Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291146287","content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n\n\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n\n\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n\n\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n\n\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2022 12:52 ET (17:52 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"CRCT":0.66,"HARP":0.9,"TERN":0.66}},"isVote":1,"tweetType":1,"viewCount":1898,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9915528738,"gmtCreate":1665076334724,"gmtModify":1676537553407,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915528738","repostId":"2273255383","repostType":2,"isVote":1,"tweetType":1,"viewCount":1510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9919401161,"gmtCreate":1663833732953,"gmtModify":1676537346296,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919401161","repostId":"2269148689","repostType":2,"isVote":1,"tweetType":1,"viewCount":1947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910691126,"gmtCreate":1663610464666,"gmtModify":1676537300344,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910691126","repostId":"2268990611","repostType":2,"isVote":1,"tweetType":1,"viewCount":1965,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910118672,"gmtCreate":1663574858396,"gmtModify":1676537293634,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910118672","repostId":"2268403626","repostType":2,"repost":{"id":"2268403626","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1663387661,"share":"https://ttm.financial/m/news/2268403626?lang=en_US&edition=fundamental","pubTime":"2022-09-17 12:07","market":"us","language":"en","title":"U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2268403626","media":"Reuters","summary":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the ","content":"<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-09-17 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4578":"CAR-T","BK4556":"基因编辑","BK4139":"生物科技"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2268403626","content_text":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy $(CALD)$, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\" (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)((mrinalika.roy@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"BLUE":1}},"isVote":1,"tweetType":1,"viewCount":1655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934677665,"gmtCreate":1663250039257,"gmtModify":1676537236428,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934677665","repostId":"2267500259","repostType":2,"repost":{"id":"2267500259","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1663238700,"share":"https://ttm.financial/m/news/2267500259?lang=en_US&edition=fundamental","pubTime":"2022-09-15 18:45","market":"hk","language":"en","title":"Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2267500259","media":"T-Reuters","summary":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Wa","content":"<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-09-15 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGEM":"Cullinan Therapeutics","LABP":"Landos Biopharma, Inc.","ONTF":"ON24, Inc.","BK4196":"保健护理服务","ADTX":"ADiTx Therapeutics","SANA":"Sana Biotechnology, Inc.","BK4023":"应用软件","BK4082":"医疗保健设备","LHDX":"Lucira Health, Inc.","BK4139":"生物科技"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2267500259","content_text":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1,"symbols_score_info":{"LHDX":0.9,"APR":0.9,"SANA":0.9,"LABP":0.9,"ONTF":0.9,"ADTX":0.9,"CGEM":0.9}},"isVote":1,"tweetType":1,"viewCount":1493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934984863,"gmtCreate":1663181239552,"gmtModify":1676537220433,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934984863","repostId":"1163730604","repostType":2,"repost":{"id":"1163730604","kind":"news","pubTimestamp":1662013072,"share":"https://ttm.financial/m/news/1163730604?lang=en_US&edition=fundamental","pubTime":"2022-09-01 14:17","market":"us","language":"en","title":"Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery","url":"https://stock-news.laohu8.com/highlight/detail?id=1163730604","media":"Bloomberg","summary":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever","content":"<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Stock’s 13,000% Surge Creates Another US IPO Mystery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-01 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MEGL":"智富融资","AMTD":"Amtd Idea","ATXG":"盈喜集团","HKD":"尚乘数科"},"source_url":"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163730604","content_text":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&P 500 Index members.Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?YokogawaAccording to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.Modest RevenuesLike Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.","news_type":1,"symbols_score_info":{"MEGL":0.9,"ATXG":0.9,"HKD":0.9,"AMTD":0.9}},"isVote":1,"tweetType":1,"viewCount":1593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9938348295,"gmtCreate":1662565020117,"gmtModify":1676537089605,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9938348295","repostId":"2265017007","repostType":2,"isVote":1,"tweetType":1,"viewCount":691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931582422,"gmtCreate":1662480247167,"gmtModify":1676537070284,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931582422","repostId":"2264753166","repostType":2,"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939595948,"gmtCreate":1662129249985,"gmtModify":1676537004260,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939595948","repostId":"2264820774","repostType":2,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939226859,"gmtCreate":1662120837471,"gmtModify":1676537002283,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939226859","repostId":"2264741732","repostType":2,"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9930623565,"gmtCreate":1661953513558,"gmtModify":1676536610788,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪💪","listText":"💪💪","text":"💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930623565","repostId":"2263407776","repostType":2,"repost":{"id":"2263407776","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1661953108,"share":"https://ttm.financial/m/news/2263407776?lang=en_US&edition=fundamental","pubTime":"2022-08-31 21:38","market":"us","language":"en","title":"BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2263407776","media":"Reuters","summary":"Aug 31 (Reuters) - Bed Bath & Beyond Inc   :   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FIN","content":"<html><body><p>Aug 31 (Reuters) - Bed Bath &amp; Beyond Inc   :</p><p>   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS</p><p>   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&amp;A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE</p><p>   * BED BATH &amp; BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY</p><p>   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN</p><p>   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH &amp; BEYOND BANNER STORES</p><p>   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&amp;A BY APPROXIMATELY $250 MILLION IN FISCAL 2022</p><p>   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE</p><p>   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM</p><p>   * BED BATH &amp; BEYOND- CONTINUES TO EVALUATE PORTFOLIO &amp; LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY</p><p>   * BED BATH &amp; BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)</p><p>   * BED BATH &amp; BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS</p><p>   * BED BATH &amp; BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL</p><p>   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021</p><p>   * BED BATH &amp; BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH &amp; BEYOND INC. PORTFOLIO</p><p>   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022</p><p>   * BED BATH &amp; BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> VALUE CREATION</p><p>   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH &amp; BEYOND</p><p>   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY</p><p>   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES</p><p>   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY</p><p>   * BED BATH &amp; BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK</p><p>   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA</p><p>   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA</p><p>   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-08-31 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aug 31 (Reuters) - Bed Bath &amp; Beyond Inc   :</p><p>   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS</p><p>   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&amp;A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE</p><p>   * BED BATH &amp; BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY</p><p>   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN</p><p>   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH &amp; BEYOND BANNER STORES</p><p>   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&amp;A BY APPROXIMATELY $250 MILLION IN FISCAL 2022</p><p>   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE</p><p>   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM</p><p>   * BED BATH &amp; BEYOND- CONTINUES TO EVALUATE PORTFOLIO &amp; LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY</p><p>   * BED BATH &amp; BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)</p><p>   * BED BATH &amp; BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS</p><p>   * BED BATH &amp; BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL</p><p>   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021</p><p>   * BED BATH &amp; BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH &amp; BEYOND INC. PORTFOLIO</p><p>   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022</p><p>   * BED BATH &amp; BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> VALUE CREATION</p><p>   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH &amp; BEYOND</p><p>   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY</p><p>   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES</p><p>   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY</p><p>   * BED BATH &amp; BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK</p><p>   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA</p><p>   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA</p><p>   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","BK4017":"黄金","BK4178":"家庭装饰零售","BK4570":"地缘局势概念股","BBBY":"Bed Bath & Beyond, Inc.","BK4547":"WSB热门概念"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263407776","content_text":"Aug 31 (Reuters) - Bed Bath & Beyond Inc   :   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE   * BED BATH & BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH & BEYOND BANNER STORES   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&A BY APPROXIMATELY $250 MILLION IN FISCAL 2022   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM   * BED BATH & BEYOND- CONTINUES TO EVALUATE PORTFOLIO & LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY   * BED BATH & BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)   * BED BATH & BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS   * BED BATH & BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021   * BED BATH & BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH & BEYOND INC. PORTFOLIO   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022   * BED BATH & BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, FUTURE VALUE CREATION   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH & BEYOND   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY   * BED BATH & BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"BBBY":1,"NGD":1}},"isVote":1,"tweetType":1,"viewCount":755,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995742906,"gmtCreate":1661524131452,"gmtModify":1676536534967,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995742906","repostId":"2262924028","repostType":2,"isVote":1,"tweetType":1,"viewCount":632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995746673,"gmtCreate":1661524004094,"gmtModify":1676536534951,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995746673","repostId":"2262927014","repostType":2,"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9992442729,"gmtCreate":1661366996163,"gmtModify":1676536503565,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep it going&nbsp;","listText":"Keep it going&nbsp;","text":"Keep it going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9992442729","repostId":"2262567869","repostType":2,"repost":{"id":"2262567869","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1661365560,"share":"https://ttm.financial/m/news/2262567869?lang=en_US&edition=fundamental","pubTime":"2022-08-25 02:26","market":"us","language":"en","title":"Trending: Bed Bath & Beyond Finds a Lender, Sources Say","url":"https://stock-news.laohu8.com/highlight/detail?id=2262567869","media":"Dow Jones","summary":"14:26 ET -- Bed Bath & Beyond Inc. is one of the most talked-about companies in the U.S. across all ","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  14:26 ET -- Bed Bath &amp; Beyond Inc. is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The home goods retailer disclosed it has a lender for a loan deal to help provide liquidity, according to people familiar with the matter. The Wall Street Journal previously reported the company was seeking about $375 million to help cash levels and pay down debt. Terms of the possible final deal weren't disclosed. Dow Jones &amp; Co. owns Factiva.(jennifer.tershak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 24, 2022 14:26 ET (18:26 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Bed Bath & Beyond Finds a Lender, Sources Say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Bed Bath & Beyond Finds a Lender, Sources Say\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-25 02:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  14:26 ET -- Bed Bath &amp; Beyond Inc. is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The home goods retailer disclosed it has a lender for a loan deal to help provide liquidity, according to people familiar with the matter. The Wall Street Journal previously reported the company was seeking about $375 million to help cash levels and pay down debt. Terms of the possible final deal weren't disclosed. Dow Jones &amp; Co. owns Factiva.(jennifer.tershak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 24, 2022 14:26 ET (18:26 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4547":"WSB热门概念","BBBY":"Bed Bath & Beyond, Inc.","BK4178":"家庭装饰零售"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2262567869","content_text":"14:26 ET -- Bed Bath & Beyond Inc. is one of the most talked-about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The home goods retailer disclosed it has a lender for a loan deal to help provide liquidity, according to people familiar with the matter. The Wall Street Journal previously reported the company was seeking about $375 million to help cash levels and pay down debt. Terms of the possible final deal weren't disclosed. Dow Jones & Co. owns Factiva.(jennifer.tershak@wsj.com) \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 24, 2022 14:26 ET (18:26 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"BBBY":1}},"isVote":1,"tweetType":1,"viewCount":626,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9992493616,"gmtCreate":1661350470538,"gmtModify":1676536501348,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep it going&nbsp;","listText":"Keep it going&nbsp;","text":"Keep it going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9992493616","repostId":"1143885737","repostType":2,"repost":{"id":"1143885737","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1661328234,"share":"https://ttm.financial/m/news/1143885737?lang=en_US&edition=fundamental","pubTime":"2022-08-24 16:03","market":"us","language":"en","title":"Starbox Shares Jumped 22% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1143885737","media":"Tiger Newspress","summary":"Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of li","content":"<html><head></head><body><p>Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of listing.</p><p><img src=\"https://static.tigerbbs.com/425e5563e091dc36b24955774a3cccb4\" tg-width=\"1407\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Malaysia-based fintech <a href=\"https://laohu8.com/S/STBX\">Starbox</a> Group (NASDAQ:STBX) saw its shares once soared as high as 1,055% on Tuesday in the wake of its $20M initial public offering.</p><p>Shares of Starbox opened at $27, rocketing to a high of $46.21 before dropping to $15.40.</p><p>Starbox offered 5M shares priced at $4 per share, raising around $20M. The company provides cash rebate, digital advertising and payment solution services to micro, small and medium-sized businesses.</p><p>Shares were priced at the lower end of its previously proposed range of $4 to $5 per share.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Starbox Shares Jumped 22% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStarbox Shares Jumped 22% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-08-24 16:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of listing.</p><p><img src=\"https://static.tigerbbs.com/425e5563e091dc36b24955774a3cccb4\" tg-width=\"1407\" tg-height=\"606\" referrerpolicy=\"no-referrer\"/></p><p>Malaysia-based fintech <a href=\"https://laohu8.com/S/STBX\">Starbox</a> Group (NASDAQ:STBX) saw its shares once soared as high as 1,055% on Tuesday in the wake of its $20M initial public offering.</p><p>Shares of Starbox opened at $27, rocketing to a high of $46.21 before dropping to $15.40.</p><p>Starbox offered 5M shares priced at $4 per share, raising around $20M. The company provides cash rebate, digital advertising and payment solution services to micro, small and medium-sized businesses.</p><p>Shares were priced at the lower end of its previously proposed range of $4 to $5 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STBX":"Starbox"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143885737","content_text":"Starbox shares jumped 22% in premarket trading. The shares soared nearly 290% on the first day of listing.Malaysia-based fintech Starbox Group (NASDAQ:STBX) saw its shares once soared as high as 1,055% on Tuesday in the wake of its $20M initial public offering.Shares of Starbox opened at $27, rocketing to a high of $46.21 before dropping to $15.40.Starbox offered 5M shares priced at $4 per share, raising around $20M. The company provides cash rebate, digital advertising and payment solution services to micro, small and medium-sized businesses.Shares were priced at the lower end of its previously proposed range of $4 to $5 per share.","news_type":1,"symbols_score_info":{"STBX":0.9}},"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9902594590,"gmtCreate":1659719695912,"gmtModify":1704335957767,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍💪","listText":"Keep going 👍💪","text":"Keep going 👍💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902594590","repostId":"2257197900","repostType":2,"repost":{"id":"2257197900","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1659713820,"share":"https://ttm.financial/m/news/2257197900?lang=en_US&edition=fundamental","pubTime":"2022-08-05 23:37","market":"hk","language":"en","title":"Applied DNA stock surges again, for 4-day gain of more than 870%","url":"https://stock-news.laohu8.com/highlight/detail?id=2257197900","media":"Dow Jones","summary":"MW Applied DNA stock surges again, for 4-day gain of more than 870%\n\n\n  Shares of Applied DNA Scienc","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Applied DNA stock surges again, for 4-day gain of more than 870%\n</p>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/APDNW\">Applied DNA Sciences Inc</a>. <a href=\"https://laohu8.com/S/APDN\">$(APDN)$</a> jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test. Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up 64.4% year to date, while the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> Biotechnology ETF <a href=\"https://laohu8.com/S/IBB\">$(IBB)$</a> has dropped 26.2% and the S&amp;P 500  has lost 13.6%. \n</p>\n<p>\n  -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 05, 2022 11:37 ET (15:37 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied DNA stock surges again, for 4-day gain of more than 870%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied DNA stock surges again, for 4-day gain of more than 870%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-05 23:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW Applied DNA stock surges again, for 4-day gain of more than 870%\n</p>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/APDNW\">Applied DNA Sciences Inc</a>. <a href=\"https://laohu8.com/S/APDN\">$(APDN)$</a> jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test. Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up 64.4% year to date, while the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> Biotechnology ETF <a href=\"https://laohu8.com/S/IBB\">$(IBB)$</a> has dropped 26.2% and the S&amp;P 500  has lost 13.6%. \n</p>\n<p>\n  -Tomi Kilgore \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 05, 2022 11:37 ET (15:37 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","IBB":"生物科技指数ETF-iShares Nasdaq","BK4109":"特种化学制品","DNA":"Ginkgo Bioworks Holdings Inc.","APDN":"Applied DNA Sciences"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2257197900","content_text":"MW Applied DNA stock surges again, for 4-day gain of more than 870%\n\n\n  Shares of Applied DNA Sciences Inc. $(APDN)$ jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%. The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test. Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up 64.4% year to date, while the iShares Biotechnology ETF $(IBB)$ has dropped 26.2% and the S&P 500  has lost 13.6%. \n\n\n  -Tomi Kilgore \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 05, 2022 11:37 ET (15:37 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"DNA":1,"APDN":0.9,"IBB":0.9}},"isVote":1,"tweetType":1,"viewCount":697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9062752274,"gmtCreate":1652110674899,"gmtModify":1676535031788,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ZYME\">$Zymeworks Inc.(ZYME)$</a>&nbsp;do people realise that the projected&nbsp;share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?&nbsp;","listText":"<a href=\"https://ttm.financial/S/ZYME\">$Zymeworks Inc.(ZYME)$</a>&nbsp;do people realise that the projected&nbsp;share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?&nbsp;","text":"$Zymeworks Inc.(ZYME)$ do people realise that the projected share price from analysts are in the range of $15 to 45?! 😅 However, Zymeworks is falling to its all time low 🤯 how?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9062752274","isVote":1,"tweetType":1,"viewCount":1283,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000701","authorId":"9000000000000701","name":"AthenaVeblen","avatar":"https://static.tigerbbs.com/fb48733f77d50133639e148b840f87ae","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000701","authorIdStr":"9000000000000701"},"content":"Now the change of stock price is difficult to explain in theory.","text":"Now the change of stock price is difficult to explain in theory.","html":"Now the change of stock price is difficult to explain in theory."},{"author":{"id":"9000000000000420","authorId":"9000000000000420","name":"PorterLamb","avatar":"https://static.tigerbbs.com/bf65ca86aeb00567f8edf7489edd03ae","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000420","authorIdStr":"9000000000000420"},"content":"Analysts will analyze from a positive point of view, so their estimated prices tend to be high.","text":"Analysts will analyze from a positive point of view, so their estimated prices tend to be high.","html":"Analysts will analyze from a positive point of view, so their estimated prices tend to be high."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081339814,"gmtCreate":1650193945166,"gmtModify":1676534666571,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along&nbsp;","listText":"Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along&nbsp;","text":"Absolutely gambling and draws in the opportunists before dropping us all in it. Not exactly a skill but just how long you want to tag along","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081339814","repostId":"2227673974","repostType":2,"isVote":1,"tweetType":1,"viewCount":485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9067643730,"gmtCreate":1652458509720,"gmtModify":1676535105022,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ASNS\">$Actelis Networks Inc(ASNS)$</a>&nbsp;does this look like $4 a share?! 😅","listText":"<a href=\"https://ttm.financial/S/ASNS\">$Actelis Networks Inc(ASNS)$</a>&nbsp;does this look like $4 a share?! 😅","text":"$Actelis Networks Inc(ASNS)$ does this look like $4 a share?! 😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9067643730","isVote":1,"tweetType":1,"viewCount":1072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934984863,"gmtCreate":1663181239552,"gmtModify":1676537220433,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934984863","repostId":"1163730604","repostType":2,"repost":{"id":"1163730604","kind":"news","pubTimestamp":1662013072,"share":"https://ttm.financial/m/news/1163730604?lang=en_US&edition=fundamental","pubTime":"2022-09-01 14:17","market":"us","language":"en","title":"Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery","url":"https://stock-news.laohu8.com/highlight/detail?id=1163730604","media":"Bloomberg","summary":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever","content":"<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Stock’s 13,000% Surge Creates Another US IPO Mystery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-01 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MEGL":"智富融资","AMTD":"Amtd Idea","ATXG":"盈喜集团","HKD":"尚乘数科"},"source_url":"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163730604","content_text":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&P 500 Index members.Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?YokogawaAccording to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.Modest RevenuesLike Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.","news_type":1,"symbols_score_info":{"MEGL":0.9,"ATXG":0.9,"HKD":0.9,"AMTD":0.9}},"isVote":1,"tweetType":1,"viewCount":1593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943069212,"gmtCreate":1678970053837,"gmtModify":1678970057873,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep the faith&nbsp;","listText":"Keep the faith&nbsp;","text":"Keep the faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943069212","repostId":"2319635989","repostType":2,"isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926346415,"gmtCreate":1671475343437,"gmtModify":1676538542689,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926346415","repostId":"2292878348","repostType":2,"isVote":1,"tweetType":1,"viewCount":1964,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919543,"gmtCreate":1670952901482,"gmtModify":1676538466261,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919543","repostId":"2291739039","repostType":2,"isVote":1,"tweetType":1,"viewCount":4025,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919295,"gmtCreate":1670952878417,"gmtModify":1676538466259,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919295","repostId":"2291146287","repostType":2,"repost":{"id":"2291146287","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1670867520,"share":"https://ttm.financial/m/news/2291146287?lang=en_US&edition=fundamental","pubTime":"2022-12-13 01:52","market":"us","language":"en","title":"Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2291146287","media":"Dow Jones","summary":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarpoon Therapeutics Shares Up 90% on Interim Data From Relapsed/Refractory Multiple Myeloma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-12-13 01:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HARP\">Harpoon Therapeutics Inc.</a> surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n</p>\n<p>\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n</p>\n<p>\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n</p>\n<p>\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n</p>\n<p>\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2022 12:52 ET (17:52 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRCT":"Cricut, Inc.","BK4139":"生物科技","BK4007":"制药","BK4191":"家用电器","BK4539":"次新股","TERN":"Terns Pharmaceuticals, Inc.","HARP":"Harpoon Therapeutics Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291146287","content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Harpoon Therapeutics Inc. surged 90% to $2.19 on Monday after the clinical-stage immuno-oncology company developing novel T cell engagers presented interim data from its trial targeting relapsed/refractory multiple myeloma. \n\n\n  Shares reached an intraday high on Monday of $3.35, a level last seen April 13 when shares reached a high of $3.42, according to FactSet. For the year, shares traded 71% lower. \n\n\n  Harpoon said its single-agent HPN217 demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM, according to the interim results. \n\n\n  A majority of responders had decreases in the serum B-cell maturation antigen biomarker by week two of treatment, the company said. Also, 86% of responders remain on study treatment with sustained response, with many responders on treatment for over a year. \n\n\n  The results were presented at the American Society of Hematology annual meeting in New Orleans. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2022 12:52 ET (17:52 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"CRCT":0.66,"HARP":0.9,"TERN":0.66}},"isVote":1,"tweetType":1,"viewCount":1898,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9915528738,"gmtCreate":1665076334724,"gmtModify":1676537553407,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915528738","repostId":"2273255383","repostType":2,"isVote":1,"tweetType":1,"viewCount":1510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9919401161,"gmtCreate":1663833732953,"gmtModify":1676537346296,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919401161","repostId":"2269148689","repostType":2,"isVote":1,"tweetType":1,"viewCount":1947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910691126,"gmtCreate":1663610464666,"gmtModify":1676537300344,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910691126","repostId":"2268990611","repostType":2,"isVote":1,"tweetType":1,"viewCount":1965,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910118672,"gmtCreate":1663574858396,"gmtModify":1676537293634,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910118672","repostId":"2268403626","repostType":2,"repost":{"id":"2268403626","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1663387661,"share":"https://ttm.financial/m/news/2268403626?lang=en_US&edition=fundamental","pubTime":"2022-09-17 12:07","market":"us","language":"en","title":"U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2268403626","media":"Reuters","summary":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the ","content":"<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-09-17 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4578":"CAR-T","BK4556":"基因编辑","BK4139":"生物科技"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2268403626","content_text":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy $(CALD)$, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\" (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)((mrinalika.roy@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"BLUE":1}},"isVote":1,"tweetType":1,"viewCount":1655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934677665,"gmtCreate":1663250039257,"gmtModify":1676537236428,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934677665","repostId":"2267500259","repostType":2,"repost":{"id":"2267500259","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1663238700,"share":"https://ttm.financial/m/news/2267500259?lang=en_US&edition=fundamental","pubTime":"2022-09-15 18:45","market":"hk","language":"en","title":"Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2267500259","media":"T-Reuters","summary":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Wa","content":"<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-09-15 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","CGEM":"Cullinan Therapeutics","LABP":"Landos Biopharma, Inc.","ONTF":"ON24, Inc.","BK4196":"保健护理服务","ADTX":"ADiTx Therapeutics","SANA":"Sana Biotechnology, Inc.","BK4023":"应用软件","BK4082":"医疗保健设备","LHDX":"Lucira Health, Inc.","BK4139":"生物科技"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2267500259","content_text":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1,"symbols_score_info":{"LHDX":0.9,"APR":0.9,"SANA":0.9,"LABP":0.9,"ONTF":0.9,"ADTX":0.9,"CGEM":0.9}},"isVote":1,"tweetType":1,"viewCount":1493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9938348295,"gmtCreate":1662565020117,"gmtModify":1676537089605,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9938348295","repostId":"2265017007","repostType":2,"isVote":1,"tweetType":1,"viewCount":691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9931582422,"gmtCreate":1662480247167,"gmtModify":1676537070284,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9931582422","repostId":"2264753166","repostType":2,"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939595948,"gmtCreate":1662129249985,"gmtModify":1676537004260,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939595948","repostId":"2264820774","repostType":2,"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9939226859,"gmtCreate":1662120837471,"gmtModify":1676537002283,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939226859","repostId":"2264741732","repostType":2,"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9930623565,"gmtCreate":1661953513558,"gmtModify":1676536610788,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"💪💪","listText":"💪💪","text":"💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9930623565","repostId":"2263407776","repostType":2,"repost":{"id":"2263407776","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1661953108,"share":"https://ttm.financial/m/news/2263407776?lang=en_US&edition=fundamental","pubTime":"2022-08-31 21:38","market":"us","language":"en","title":"BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2263407776","media":"Reuters","summary":"Aug 31 (Reuters) - Bed Bath & Beyond Inc   :   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FIN","content":"<html><body><p>Aug 31 (Reuters) - Bed Bath &amp; Beyond Inc   :</p><p>   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS</p><p>   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&amp;A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE</p><p>   * BED BATH &amp; BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY</p><p>   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN</p><p>   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH &amp; BEYOND BANNER STORES</p><p>   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&amp;A BY APPROXIMATELY $250 MILLION IN FISCAL 2022</p><p>   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE</p><p>   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM</p><p>   * BED BATH &amp; BEYOND- CONTINUES TO EVALUATE PORTFOLIO &amp; LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY</p><p>   * BED BATH &amp; BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)</p><p>   * BED BATH &amp; BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS</p><p>   * BED BATH &amp; BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL</p><p>   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021</p><p>   * BED BATH &amp; BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH &amp; BEYOND INC. PORTFOLIO</p><p>   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022</p><p>   * BED BATH &amp; BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> VALUE CREATION</p><p>   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH &amp; BEYOND</p><p>   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY</p><p>   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES</p><p>   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY</p><p>   * BED BATH &amp; BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK</p><p>   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA</p><p>   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA</p><p>   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bed Bath & Beyond Says It Secured Commitments For More Than $500 Mln Of New Financing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-08-31 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aug 31 (Reuters) - Bed Bath &amp; Beyond Inc   :</p><p>   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS</p><p>   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&amp;A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE</p><p>   * BED BATH &amp; BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY</p><p>   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN</p><p>   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH &amp; BEYOND BANNER STORES</p><p>   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&amp;A BY APPROXIMATELY $250 MILLION IN FISCAL 2022</p><p>   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING</p><p>   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION</p><p>   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE</p><p>   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM</p><p>   * BED BATH &amp; BEYOND- CONTINUES TO EVALUATE PORTFOLIO &amp; LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY</p><p>   * BED BATH &amp; BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)</p><p>   * BED BATH &amp; BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS</p><p>   * BED BATH &amp; BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL</p><p>   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021</p><p>   * BED BATH &amp; BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH &amp; BEYOND INC. PORTFOLIO</p><p>   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022</p><p>   * BED BATH &amp; BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> VALUE CREATION</p><p>   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH &amp; BEYOND</p><p>   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY</p><p>   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES</p><p>   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY</p><p>   * BED BATH &amp; BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK</p><p>   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA</p><p>   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA</p><p>   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLION</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","BK4017":"黄金","BK4178":"家庭装饰零售","BK4570":"地缘局势概念股","BBBY":"Bed Bath & Beyond, Inc.","BK4547":"WSB热门概念"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2263407776","content_text":"Aug 31 (Reuters) - Bed Bath & Beyond Inc   :   * . ANNOUNCES STRATEGIC CHANGES TO STRENGTHEN ITS FINANCIAL POSITIONING, DRIVE GROWTH AND BETTER SERVE CUSTOMERS   * SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING   * ANNOUNCED IT HAS SECURED FINANCING COMMITMENTS FOR MORE THAN $500 MILLION OF NEW FINANCING   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION   * HAS BEGUN IMPLEMENTING SIGNIFICANT, ADDITIONAL SG&A REDUCTIONS TO RIGHT-SIZE ITS COST STRUCTURE   * BED BATH & BEYOND - SECURED FINANCING COMMITMENTS INCLUDING ITS NEWLY EXPANDED $1.13 BILLION ABL FACILITY AND A NEW $375 MILLION FILO FACILITY   * COST OPTIMIZATION PLANS INCLUDE A REDUCTION IN FORCE, INCLUDING APPROXIMATELY 20% ACROSS CORPORATE AND SUPPLY CHAIN   * IDENTIFIED AND COMMENCED CLOSURE OF APPROXIMATELY 150 LOWER-PRODUCING BED BATH & BEYOND BANNER STORES   * EXPECTS ACTIONS ANNOUNCED TODAY TO REDUCE SG&A BY APPROXIMATELY $250 MILLION IN FISCAL 2022   * HAS FURTHER REDUCED ITS PLAN FOR CAPITAL SPENDING   * IN FISCAL 2022, PLANNED CAPITAL EXPENDITURES ARE NOW FORECASTED TO BE $250 MILLION   * WORKING EXPEDITIOUSLY TO INCREASE ITS NATIONAL BRANDS INVENTORY WHERE POSSIBLE   * WILL INCREASE INVENTORY PENETRATION BY 20 PERCENTAGE POINTS OVER LONG TERM   * BED BATH & BEYOND- CONTINUES TO EVALUATE PORTFOLIO & LEASES, IN ADDITION TO STAFFING, TO ENSURE ALIGNMENT WITH CUSTOMER DEMAND AND GO-FORWARD STRATEGY   * BED BATH & BEYOND - WILL BE EXITING A THIRD OF ITS OWNED BRANDS BY DISCONTINUING THREE OF ITS NINE LABELS (HAVEN™, WILD SAGE™ AND STUDIO 3B™)   * BED BATH & BEYOND - BREADTH AND DEPTH OF INVENTORY ACROSS COMPANY'S SIX REMAINING OWNED BRANDS WILL BE SUBSTANTIALLY REDUCED TO 20 PERCENTAGE POINTS   * BED BATH & BEYOND - COMPLETED A COMPREHENSIVE REVIEW OF INHERENT VALUE OF COMPANY'S BUYBUY BABY BANNER, WHICH CONFIRMED BANNER'S STRATEGIC POTENTIAL   * SEES Q2 COMPARABLE SALES DECLINE OF APPROXIMATELY 26% COMPARED TO Q2 OF FISCAL 2021   * BED BATH & BEYOND - BOARD BELIEVES , AT THIS TIME, BUYBUY BABY WILL DELIVER GREATER VALUE FOR SHAREHOLDERS AS PART OF BED BATH & BEYOND INC. PORTFOLIO   * SEES COMPARABLE SALES DECLINE IN 20% RANGE DRIVEN BY IMPROVEMENTS IN SECOND HALF OF FISCAL 2022 VERSUS FIRST HALF OF FISCAL 2022   * BED BATH & BEYOND - BOARD OF DIRECTORS' STRATEGY COMMITTEE TO CONTINUE TO MONITOR BUYBUY BABY BUSINESS AS IT PRESERVES OPTIONALITY, FUTURE VALUE CREATION   * MARA SIRHAL HAS BEEN APPOINTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BED BATH & BEYOND   * PATTY WU HAS BEEN PROMOTED TO EXECUTIVE VICE PRESIDENT AND BRAND PRESIDENT OF BUYBUY BABY   * HAS ELIMINATED CHIEF OPERATING OFFICER AND CHIEF STORES OFFICER ROLES   * JOHN HARTMANN AND GREGG MELNICK WILL BE DEPARTING COMPANY   * BED BATH & BEYOND - FILED FORM S-3 REGISTRATION STATEMENT AS IT PREPARES FOR POTENTIAL LAUNCH OF ATM PROGRAM FOR UP TO 12 MILLION SHARES OF COMMON STOCK   * Q2 REVENUE VIEW $1.50 BILLION -- REFINITIV IBES DATA   * FY2022 REVENUE VIEW $7.88 BILLION -- REFINITIV IBES DATA   * SEES Q2 NET SALES OF APPROXIMATELY $1.45 BILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"BBBY":1,"NGD":1}},"isVote":1,"tweetType":1,"viewCount":755,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995742906,"gmtCreate":1661524131452,"gmtModify":1676536534967,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995742906","repostId":"2262924028","repostType":2,"isVote":1,"tweetType":1,"viewCount":632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9995746673,"gmtCreate":1661524004094,"gmtModify":1676536534951,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099579894850160","authorIdStr":"4099579894850160"},"themes":[],"htmlText":"Keep going&nbsp;","listText":"Keep going&nbsp;","text":"Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9995746673","repostId":"2262927014","repostType":2,"repost":{"id":"2262927014","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1661523441,"share":"https://ttm.financial/m/news/2262927014?lang=en_US&edition=fundamental","pubTime":"2022-08-26 22:17","market":"hk","language":"en","title":"Dow, S&P 500 Edge Lower Following Powell's Comments","url":"https://stock-news.laohu8.com/highlight/detail?id=2262927014","media":"Benzinga","summary":"U.S. stocks traded mostly lower this morning, following comments from the Fed chief Jerome Powell.","content":"<html><body><p>U.S. stocks traded mostly lower this morning, following comments from the Fed chief Jerome Powell.</p>\n<p>The Dow traded down 0.13% to 33,248.66 while the NASDAQ fell 0.17% to 12,617.92. The S&amp;P 500 also fell, dropping, 0.20% to 4,190.84.\n\n<em>Also check this: Bitcoin, Ethereum Record Losses Ahead Of Powell's Speech; Here Are The Top Crypto Movers For Friday </em></p>\n<p>\n<strong>Leading and Lagging Sectors</strong></p>\n<p>\r\nUtilities shares rose by 0.1% on Friday. Meanwhile, top gainers in the sector included <strong> Unitil Corporation</strong> (NYSE:UTL), up 1% and <strong> TransAlta Corporation</strong> (NYSE:TAC) up 1%.</p>\n<p>\r\nIn trading on Friday, communication services shares dipped by 1.1%.</p>\n<p>\n<strong>Top Headline</strong></p>\n<p>\r\nU.S. personal spending rose 0.1% month-over-month in July, while personal income increased 0.2%. The personal consumption expenditure price index declined 0.1% month-over-month in July after increasing 1% in June.</p>\n<p>\n<strong>Equities Trading UP</strong></p>\n<p>\n<strong>Micro Focus International plc</strong> (NYSE:MFGP) shares shot up 95% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion.</p>\n<p>Shares of <strong> <a href=\"https://laohu8.com/S/DRUG\">Bright Minds Biosciences Inc</a>. </strong> (NASDAQ:DRUG) got a boost, shooting 20% to $3.4786. Bright Minds recently priced overnight marketed offering of 2.858 million units at $1.40 per unit.</p>\n<p><strong><a href=\"https://laohu8.com/S/AKLI\">Akili, Inc.</a> </strong> (NASDAQ:AKLI) shares were also up, gaining 24% to $5.13 after dropping 20% on Thursday.</p>\n<p><strong>Equities Trading DOWN</strong></p>\n<p><strong>Domo, Inc.</strong> (NASDAQ:DOMO) shares tumbled 25% to $21.61 after the company reported worse-than-expected Q2 sales results and issued Q3 and FY23 sales guidance below analyst estimates. Additionally, multiple analysts lowered their price target on the stock.</p>\n<p>\r\nShares of <strong> <a href=\"https://laohu8.com/S/MOB\">Mobilicom Limited</a></strong> (NASDAQ:MOB) were down 21% to $4.33 on possible profit taking after the stock surged yesterday following its IPO debut.</p>\n<p>\n<strong><a href=\"https://laohu8.com/S/VEEE\">Twin Vee Powercats Co</a>.</strong> (NASDAQ:VEEE) was down, falling 18% to $4.55.</p>\n<p>\n<em>Also check out: Market Volatility Decreases Further As Investors Await Powell Speech </em></p>\n<p>\n<strong>Commodities</strong></p>\n<p>In commodity news, oil traded down 0.3% to $92.25, while gold traded up 0.4% to $1,763.90.</p>\n<p>\r\nSilver traded up 0.8% to $19.27 on Friday while copper rose 1.5% to $3.7545.</p>\n<p>\n<strong>Euro zone</strong></p>\n<p>\r\nEuropean shares were mostly lower today. The eurozone’s STOXX 600 fell 0.6%, London’s FTSE 100 fell 0.1% while Spain’s IBEX 35 Index fell 0.7%. The German DAX declined 0.6%, French CAC 40 fell 0.6% and Italy’s FTSE MIB Index dipped 1.2%.</p>\n<p>Loans to households in the Eurozone increased 4.5% year-over-year in July. Italian consumer confidence climbed by 3.5 points to 98.3 in August from 94.8 a month ago, while manufacturing confidence declined by 2.1 points to 104.3 in August.</p>\n<p>The consumer confidence index in France rose to 82 in August from 80 in July, while GfK Consumer Climate Indicator for Germany declined to a fresh record low level of -36.5 heading into September.</p>\n<p><strong>Economics</strong></p>\n<p>The US goods trade deficit shrank to $89.1 billion in July from a revised $98.6 billion in the prior month.</p>\n<p>\r\nU.S. personal spending rose 0.1% month-over-month in July, while personal income increased 0.2%. The personal consumption expenditure price index declined 0.1% month-over-month in July after increasing 1% in June.</p>\n<p>\r\nWholesale inventories rose by 0.8% month-over-month to $902.9 billion in July.</p>\n<p>\r\nThe University of Michigan consumer sentiment was revised higher to 58.2 in August from a preliminary reading of 55.1.</p>\n<p>\r\nThe Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.</p>\n<p><em>Check out this: Investor Sentiment Improves With Powell's Speech In Focus</em></p>\n<p>\n<strong>COVID-19 Update</strong></p>\n<p>The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 95,844,670 cases with around 1,068,110 deaths. India confirmed a total of at least 44,389,170 cases and 527,550 deaths, while France reported over 34,428,730 COVID-19 cases with 153,800 deaths. In total, there were at least 604,479,650 cases of COVID-19 worldwide with more than 6,483,560 deaths.\r\n</p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow, S&P 500 Edge Lower Following Powell's Comments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow, S&P 500 Edge Lower Following Powell's Comments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-08-26 22:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>U.S. stocks traded mostly lower this morning, following comments from the Fed chief Jerome Powell.</p>\n<p>The Dow traded down 0.13% to 33,248.66 while the NASDAQ fell 0.17% to 12,617.92. The S&amp;P 500 also fell, dropping, 0.20% to 4,190.84.\n\n<em>Also check this: Bitcoin, Ethereum Record Losses Ahead Of Powell's Speech; Here Are The Top Crypto Movers For Friday </em></p>\n<p>\n<strong>Leading and Lagging Sectors</strong></p>\n<p>\r\nUtilities shares rose by 0.1% on Friday. Meanwhile, top gainers in the sector included <strong> Unitil Corporation</strong> (NYSE:UTL), up 1% and <strong> TransAlta Corporation</strong> (NYSE:TAC) up 1%.</p>\n<p>\r\nIn trading on Friday, communication services shares dipped by 1.1%.</p>\n<p>\n<strong>Top Headline</strong></p>\n<p>\r\nU.S. personal spending rose 0.1% month-over-month in July, while personal income increased 0.2%. The personal consumption expenditure price index declined 0.1% month-over-month in July after increasing 1% in June.</p>\n<p>\n<strong>Equities Trading UP</strong></p>\n<p>\n<strong>Micro Focus International plc</strong> (NYSE:MFGP) shares shot up 95% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion.</p>\n<p>Shares of <strong> <a href=\"https://laohu8.com/S/DRUG\">Bright Minds Biosciences Inc</a>. </strong> (NASDAQ:DRUG) got a boost, shooting 20% to $3.4786. Bright Minds recently priced overnight marketed offering of 2.858 million units at $1.40 per unit.</p>\n<p><strong><a href=\"https://laohu8.com/S/AKLI\">Akili, Inc.</a> </strong> (NASDAQ:AKLI) shares were also up, gaining 24% to $5.13 after dropping 20% on Thursday.</p>\n<p><strong>Equities Trading DOWN</strong></p>\n<p><strong>Domo, Inc.</strong> (NASDAQ:DOMO) shares tumbled 25% to $21.61 after the company reported worse-than-expected Q2 sales results and issued Q3 and FY23 sales guidance below analyst estimates. Additionally, multiple analysts lowered their price target on the stock.</p>\n<p>\r\nShares of <strong> <a href=\"https://laohu8.com/S/MOB\">Mobilicom Limited</a></strong> (NASDAQ:MOB) were down 21% to $4.33 on possible profit taking after the stock surged yesterday following its IPO debut.</p>\n<p>\n<strong><a href=\"https://laohu8.com/S/VEEE\">Twin Vee Powercats Co</a>.</strong> (NASDAQ:VEEE) was down, falling 18% to $4.55.</p>\n<p>\n<em>Also check out: Market Volatility Decreases Further As Investors Await Powell Speech </em></p>\n<p>\n<strong>Commodities</strong></p>\n<p>In commodity news, oil traded down 0.3% to $92.25, while gold traded up 0.4% to $1,763.90.</p>\n<p>\r\nSilver traded up 0.8% to $19.27 on Friday while copper rose 1.5% to $3.7545.</p>\n<p>\n<strong>Euro zone</strong></p>\n<p>\r\nEuropean shares were mostly lower today. The eurozone’s STOXX 600 fell 0.6%, London’s FTSE 100 fell 0.1% while Spain’s IBEX 35 Index fell 0.7%. The German DAX declined 0.6%, French CAC 40 fell 0.6% and Italy’s FTSE MIB Index dipped 1.2%.</p>\n<p>Loans to households in the Eurozone increased 4.5% year-over-year in July. Italian consumer confidence climbed by 3.5 points to 98.3 in August from 94.8 a month ago, while manufacturing confidence declined by 2.1 points to 104.3 in August.</p>\n<p>The consumer confidence index in France rose to 82 in August from 80 in July, while GfK Consumer Climate Indicator for Germany declined to a fresh record low level of -36.5 heading into September.</p>\n<p><strong>Economics</strong></p>\n<p>The US goods trade deficit shrank to $89.1 billion in July from a revised $98.6 billion in the prior month.</p>\n<p>\r\nU.S. personal spending rose 0.1% month-over-month in July, while personal income increased 0.2%. The personal consumption expenditure price index declined 0.1% month-over-month in July after increasing 1% in June.</p>\n<p>\r\nWholesale inventories rose by 0.8% month-over-month to $902.9 billion in July.</p>\n<p>\r\nThe University of Michigan consumer sentiment was revised higher to 58.2 in August from a preliminary reading of 55.1.</p>\n<p>\r\nThe Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.</p>\n<p><em>Check out this: Investor Sentiment Improves With Powell's Speech In Focus</em></p>\n<p>\n<strong>COVID-19 Update</strong></p>\n<p>The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 95,844,670 cases with around 1,068,110 deaths. India confirmed a total of at least 44,389,170 cases and 527,550 deaths, while France reported over 34,428,730 COVID-19 cases with 153,800 deaths. In total, there were at least 604,479,650 cases of COVID-19 worldwide with more than 6,483,560 deaths.\r\n</p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","BK4550":"红杉资本持仓","DOMO":"Domo Inc.","IVV":"标普500ETF-iShares","SSO":"2倍做多标普500ETF-ProShares","SPY":"标普500ETF","MFGP":"Micro Focus Intl PLC","TAC":"Transalta Corp","OEF":"标普100指数ETF-iShares","BK4581":"高盛持仓","VEEE":"Twin Vee Powercats Co","BK4096":"电气部件与设备","SDS":"两倍做空标普500 ETF-ProShares","BK4534":"瑞士信贷持仓",".SPX":"S&P 500 Index","DRUG":"Bright Minds Biosciences Inc","UTL":"Unitil Corp","MOB":"Mobilicom Limited","OEX":"标普100","AKLI":"Akili, Inc.","POWL":"Powell Industries","BK4504":"桥水持仓","UPRO":"三倍做多标普500ETF-ProShares","BK4559":"巴菲特持仓","SPXU":"三倍做空标普500ETF-ProShares","SH":"做空标普500-Proshares"},"source_url":"https://www.benzinga.com/news/earnings/22/08/28650092/dow-s-p-500-edge-lower-following-powells-comments","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2262927014","content_text":"U.S. stocks traded mostly lower this morning, following comments from the Fed chief Jerome Powell.\nThe Dow traded down 0.13% to 33,248.66 while the NASDAQ fell 0.17% to 12,617.92. The S&P 500 also fell, dropping, 0.20% to 4,190.84.\n\nAlso check this: Bitcoin, Ethereum Record Losses Ahead Of Powell's Speech; Here Are The Top Crypto Movers For Friday \n\nLeading and Lagging Sectors\n\r\nUtilities shares rose by 0.1% on Friday. Meanwhile, top gainers in the sector included  Unitil Corporation (NYSE:UTL), up 1% and  TransAlta Corporation (NYSE:TAC) up 1%.\n\r\nIn trading on Friday, communication services shares dipped by 1.1%.\n\nTop Headline\n\r\nU.S. personal spending rose 0.1% month-over-month in July, while personal income increased 0.2%. The personal consumption expenditure price index declined 0.1% month-over-month in July after increasing 1% in June.\n\nEquities Trading UP\n\nMicro Focus International plc (NYSE:MFGP) shares shot up 95% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion.\nShares of  Bright Minds Biosciences Inc.  (NASDAQ:DRUG) got a boost, shooting 20% to $3.4786. Bright Minds recently priced overnight marketed offering of 2.858 million units at $1.40 per unit.\nAkili, Inc.  (NASDAQ:AKLI) shares were also up, gaining 24% to $5.13 after dropping 20% on Thursday.\nEquities Trading DOWN\nDomo, Inc. (NASDAQ:DOMO) shares tumbled 25% to $21.61 after the company reported worse-than-expected Q2 sales results and issued Q3 and FY23 sales guidance below analyst estimates. Additionally, multiple analysts lowered their price target on the stock.\n\r\nShares of  Mobilicom Limited (NASDAQ:MOB) were down 21% to $4.33 on possible profit taking after the stock surged yesterday following its IPO debut.\n\nTwin Vee Powercats Co. (NASDAQ:VEEE) was down, falling 18% to $4.55.\n\nAlso check out: Market Volatility Decreases Further As Investors Await Powell Speech \n\nCommodities\nIn commodity news, oil traded down 0.3% to $92.25, while gold traded up 0.4% to $1,763.90.\n\r\nSilver traded up 0.8% to $19.27 on Friday while copper rose 1.5% to $3.7545.\n\nEuro zone\n\r\nEuropean shares were mostly lower today. The eurozone’s STOXX 600 fell 0.6%, London’s FTSE 100 fell 0.1% while Spain’s IBEX 35 Index fell 0.7%. The German DAX declined 0.6%, French CAC 40 fell 0.6% and Italy’s FTSE MIB Index dipped 1.2%.\nLoans to households in the Eurozone increased 4.5% year-over-year in July. Italian consumer confidence climbed by 3.5 points to 98.3 in August from 94.8 a month ago, while manufacturing confidence declined by 2.1 points to 104.3 in August.\nThe consumer confidence index in France rose to 82 in August from 80 in July, while GfK Consumer Climate Indicator for Germany declined to a fresh record low level of -36.5 heading into September.\nEconomics\nThe US goods trade deficit shrank to $89.1 billion in July from a revised $98.6 billion in the prior month.\n\r\nU.S. personal spending rose 0.1% month-over-month in July, while personal income increased 0.2%. The personal consumption expenditure price index declined 0.1% month-over-month in July after increasing 1% in June.\n\r\nWholesale inventories rose by 0.8% month-over-month to $902.9 billion in July.\n\r\nThe University of Michigan consumer sentiment was revised higher to 58.2 in August from a preliminary reading of 55.1.\n\r\nThe Baker Hughes North American rig count report for the latest week is scheduled for release at 1:00 p.m. ET.\nCheck out this: Investor Sentiment Improves With Powell's Speech In Focus\n\nCOVID-19 Update\nThe U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 95,844,670 cases with around 1,068,110 deaths. India confirmed a total of at least 44,389,170 cases and 527,550 deaths, while France reported over 34,428,730 COVID-19 cases with 153,800 deaths. In total, there were at least 604,479,650 cases of COVID-19 worldwide with more than 6,483,560 deaths.","news_type":1,"symbols_score_info":{"161125":0.6,"513500":0.6,"TAC":0.9,"DRUG":0.9,"ESmain":0.6,"MFGP":0.9,"POWL":1,"UTL":0.9,"IVV":0.6,".SPX":0.6,"SPXU":0.6,"OEF":0.6,"UPRO":0.6,"SH":0.6,"SDS":0.6,"SPY":1,"VEEE":0.9,"SSO":0.6,"OEX":0.6,"MOB":0.9,"AKLI":0.9,"DOMO":0.9}},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}